These preclinical data demonstrated the ability of iSPERSE formulations to deliver stable and therapeutically-relevant drug doses across a range of flow rates, offering the potential of improved drug efficacy and safety for patients having both normal and lower or impaired lung function.
Pulmatrix chief scientific officer and research and development vice president Robert Clarke said the data show the significant potential of iSPERSE for pulmonary delivery across a diverse range of therapies, at higher drug loads with flow rate independence and enhanced delivery efficiency
"This combination of traits differentiates iSPERSE from existing approaches by enabling the possibility of therapeutic dose delivery in lower total inhaled powder masses," Clarke added.
Pulmatrix is now advancing a number of proprietary iSPERSE drug formulation candidates including small molecules, combinations and biologics in a variety of therapeutic areas.